Erasca to Present at the Bank of America Securities 2023 Health Care Conference

Jonathan is Chairman and CEO of Erasca, which he co-founded in July 2018 with a mission to erase cancer. He is a physician-turned-venturepreneur at City Hill and ARCH Venture who founds, funds and leads mission-driven for-profit and non-profit ventures. He has served as Chairman and/or CEO and founding investor of six biotechnology companies that have collectively achieved global regulatory approval and launch of seven therapeutic products in oncology, immunology and drug delivery, benefitting thousands of patients worldwide, while generating approximately $10 billion of shareholder value. Jonathan has pioneered transformative advancements in drug delivery and precision oncology.

In drug delivery, he designed and executed landmark deals for Halozyme’s ENHANZE^® drug delivery technology with Roche/Genentech and Baxter that formed the foundational business model and template for the company’s ten global alliances and five approved ENHANZE products that have enabled Halozyme to turn EBITDA positive and guide to $1 billion in royalty revenue in 2027. In precision oncology, Jonathan led Ignyta’s trailblazing pursuit of a global tissue agnostic label to transform cancer treatment with ROZLYTREK^® (entrectinib) that, in the process of securing global regulatory approvals, became the first drug in biopharmaceutical history to achieve the unprecedented triple crown of breakthrough designations with BTD (FDA), PRIME (EMA) and Sakigake (PMDA). He led the strategic process that successfully resulted in the acquisition of Ignyta to become a key personalized healthcare pillar for Roche/Genentech, the leading precision oncology company in the world. He is continuing to pursue new frontiers of precision oncology at Erasca.